Notice of Intent_75F40124Q00409.pdf
PDF 112 KB Posted
- Attached to
- Hive DRAGEN Server
- Solicitation number
- 75F40124Q00409
About this file
This document is a Notice of Intent to award a sole-source contract to Illumina, Inc. for a DRAGEN Server and associated software licenses.
The Food and Drug Administration (FDA) intends to procure a DRAGEN Appliance computing system, which uses field-programmable gate array (FPGA) technology to provide hardware acceleration for genomics analysis. Illumina is the sole provider of this FPGA-based hardware and software, and there are no other vendors that can supply the unique capabilities of the DRAGEN system. The FDA is issuing this notice under the authority of FAR 6.302-1 for a sole-source award to Illumina. Any firm that believes it can meet the requirements must submit a written response by July 10, 2024. However, the Government retains sole discretion in determining whether to compete the acquisition based on any responses received. If no responses are received, the FDA will proceed with the sole-source award to Illumina.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Hive DRAGEN Server Intent to Sole Source
FDA – 75F40124Q00409
Date Posted: July 3, 2024
Response Date: July 10, 2024, by 1:00 PM EST
Classification Code: 7B22 – IT and Telecom—Compute: Servers (Hardware and Perpetual License Software)
NAICS Code: 541519 Other Computer Related Services
The United States (US) Food and Drug Administration (FDA) intends to negotiate and award on a sole source basis to Illumina, Inc. (Illumina), 5200 Illumina Way, San Diego, CA, 92122, under the authority of FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. This acquisition is in support of the FDA’s CBER Office of Biostatistics and Epidemiology (OBE) HIVE group.
The FDA intends to procure from Illumina a server and software licenses for the DRAGEN Appliance computing system. This appliance is a computer that uses field-gate programmable array (FPGA) based technology to provide hardware acceleration for genomics analysis, including BCL conversion, mapping, alignment, sorting, duplicate marking, and haplotype variant calling. The DRAGEN Bio-IT Platform software uses the FPGA acceleration to rapidly detect variants with high sensitivity and specificity, and to analyze data from whole genomes, whole exomes, targeted panels, germline and somatic datasets, and RNA sequencing.
Illumina is the sole provider of this hardware acceleration. There are no other vendors that can create software to be used in the DRAGEN system and provide the unique nature of the FPGA hardware design, accuracy, and speed.
This notice is being published in accordance with Federal Acquisition Regulation (FAR) Part 5.101(a)(1) requiring the dissemination of information on proposed contract actions. This is a notice of intent to award a sole-source contract and is not a request for competitive proposals.
The statutory authority for this sole-source procurement is FAR 6.302-1.
This notice of intent is not a request for competitive quotations. However, any firm that believes it can meet these requirements may submit a written response via email to Alicia Baltimore at Alicia.Baltimore@fda.hhs.gov by July 10, 2024 at 1:00 PM Eastern Standard Time (EST).
Supporting evidence must be furnished in sufficient detail to demonstrate the ability to comply with the above requirement. Information received will be considered; however, a determination by the Government not to compete the proposed acquisition based on responses to this notice is solely within the discretion of the Government. If no responses are received, the FDA will proceed with the sole source award to Illumina, Inc. No telephonic inquiries.
mailto:Alicia.Baltimore@fda.hhs.gov
File details come from the government source that posted it. Updated .